Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of topical ozenoxacin (M512102) for impetigo
jRCT2080224574Phase 3Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ozenoxacin in impetigo (2 arms), sponsored by Maruho Co., Ltd. Primary endpoints: Efficacy outcomes, Safety outcomes and 1 more. Started Feb 2019; status: completed.
02
Drugs
ozenoxacin
03
Conditions
impetigo
Beyond the preview
Go deeper on jRCT2080224574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224574.